naltrexone has been researched along with olanzapine in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (7.14) | 29.6817 |
| 2010's | 15 (35.71) | 24.3611 |
| 2020's | 24 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borsook, D; Currie, PJ; Elman, I; Kurbanov, DB; Simonson, DC | 1 |
| Amos, T; Chamberlain, SR; Fineberg, N; Ipser, JC; Rothbart, R; Siegfried, N; Stein, DJ | 1 |
| Borsook, D; Elman, I; Langleben, DD; Simonson, DC; Swift, R; Taveira, TH; Tschibelu, E; Wu, WC; Yamamoto, R | 1 |
| Hackett, D; Heal, DJ; Hutson, PH; Murray, F; Vickers, SP | 1 |
| Correll, CU; DiPetrillo, L; Kane, JM; Martin, W; Memisoglu, A; Silverman, BL | 1 |
| Liu, J; McDonnell, D; Sun, L; von Moltke, L | 1 |
| McDonnell, D; Sun, L; von Moltke, L | 1 |
| Correll, CU; DiPetrillo, L; Ehrich, EW; Jiang, Y; Martin, WF; Pathak, S; Silverman, BL; Weiden, PJ | 1 |
| Kumar, V; McDonnell, D; Sun, L; von Moltke, L; Yu, M | 1 |
| Cunningham, JI; Dean, RL; Deaver, DR; Eyerman, DJ; Namchuk, M; Sanchez, C; Todtenkopf, MS | 1 |
| Graham, C; Sun, L; von Moltke, L; Yagoda, S; Yao, B | 1 |
| Du, Y; Sun, L; von Moltke, L; Yagoda, S | 1 |
| Rowland Yeo, K; Sun, L; von Moltke, L | 2 |
| Brown, R; Darpo, B; McDonnell, D; Nangia, N; Rege, B; Sun, L; von Moltke, L; Xue, H; Yagoda, S | 1 |
| DiPetrillo, L; Jiang, Y; Kunovac, J; McDonnell, D; Potkin, SG; Silverman, BL; Simmons, A | 1 |
| Brunette, MF; Citrome, L; Correll, CU; DiPetrillo, L; Green, AI; Jiang, Y; McDonnell, D; O'Malley, SS; Silverman, BL; Simmons, A | 1 |
| Arevalo, C; Graham, C; Jiang, Y; McDonnell, D; Simmons, A; Yagoda, S | 1 |
| Correll, CU; DiPetrillo, L; Du, Y; Graham, C; Hopkinson, C; Jiang, Y; Kahn, RS; McDonnell, D; Newcomer, JW; Silverman, B; Simmons, A | 1 |
| Buchanan, RW | 1 |
| Likhitsathian, S; Maneeton, B; Maneeton, N; Srisurapanont, M; Suttajit, S | 1 |
| Bhupathi, V; DiPetrillo, L; Graham, C; Hopkinson, C; Jiang, Y; Kahn, RS; McDonnell, D; Silverman, BL; Simmons, A; Yagoda, S; Yin, J; Yu, B | 1 |
| Mills, R; Rege, B; Sadler, BM; Sun, L | 1 |
| Barter, Z; Rowland Yeo, K; Sun, L; von Moltke, L | 1 |
| Paik, J | 1 |
| Bajorunas, D; Beysen, C; Graham, C; Jiang, Y; Martin, WF; McDonnell, D; Morrow, L; Namchuk, MN; Newcomer, JW; Silverman, BL; Toledo, FGS | 1 |
| Alnefeesi, Y; Ceban, F; Chen-Li, DCJ; Gillissie, ES; Jaberi, S; Jawad, MY; Lui, LMW; McIntyre, RS; Rosenblat, JD; Teopiz, K; Vincenzo, JDD | 1 |
| Gums, JG; McCoy, L; Monahan, C; Powell, J | 1 |
| Akerman, S; Citrome, L; Cummings, H; McIntyre, RS; Tan, LA; Todtenkopf, MS; White, M | 1 |
| Elaraby, M; Elkhateeb, AE; Gamal, A; Madian, H; Mazen, DZ; Rasekh, MI; Salem, H; Samir, E | 1 |
| Schmitz, ZP; Soghoian, SE; Warstadt, NM | 1 |
| Citrome, L; Faden, J; Serdenes, R | 1 |
| Corrao, MM; Nelson, LA | 1 |
| Gao, J; Li, J; Lu, X; Yang, J | 1 |
| Bowden-Jones, H; Cowlishaw, S; Dowling, N; Lubman, D; Merkouris, S; Thomas, S | 1 |
11 review(s) available for naltrexone and olanzapine
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy for trichotillomania.
Topics: Acetylcysteine; Adult; Benzodiazepines; Clomipramine; Humans; Naltrexone; Olanzapine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trichotillomania | 2013 |
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
Topics: Antipsychotic Agents; Cardiometabolic Risk Factors; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Naltrexone; Olanzapine; Schizophrenia; Weight Gain | 2021 |
Olanzapine/Samidorphan: First Approval.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain | 2021 |
Olanzapine and samidorphan combination treatment: A systematic review.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Naltrexone; Narcotic Antagonists; Olanzapine | 2022 |
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Olanzapine; Schizophrenia | 2022 |
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
Topics: Analgesics, Opioid; Antipsychotic Agents; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Receptors, Opioid, kappa; Weight Gain | 2023 |
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Tablets; Weight Gain | 2022 |
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
Topics: Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Olanzapine; Schizophrenia; Weight Gain | 2022 |
Pharmacological interventions for the treatment of disordered and problem gambling.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Gambling; Headache; Humans; Naltrexone; Narcotic Antagonists; Nausea; Olanzapine | 2022 |
14 trial(s) available for naltrexone and olanzapine
| Article | Year |
|---|---|
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
Topics: Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Humans; Insulin Resistance; Lipids; Liver Function Tests; Male; Middle Aged; Naltrexone; Olanzapine; Pilot Projects; Psychotic Disorders; Schizophrenia; Young Adult | 2014 |
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Naltrexone; Narcotic Antagonists; Olanzapine; Time Factors; Weight Gain; Young Adult | 2018 |
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Combinations; Female; Healthy Volunteers; Humans; Male; Naltrexone; Olanzapine; Tablets; Therapeutic Equivalency; Young Adult | 2019 |
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chromatography, Liquid; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Olanzapine; Schizophrenia; Tandem Mass Spectrometry; Weight Gain | 2018 |
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Constipation; Dizziness; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Sleepiness; Weight Gain | 2019 |
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Rifampin; Weight Gain; Young Adult | 2019 |
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Male; Middle Aged; Naltrexone; Olanzapine; Renal Insufficiency; Tablets; Young Adult | 2019 |
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia | 2020 |
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Outcome Assessment, Health Care; Schizophrenia; Symptom Flare Up | 2020 |
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Outcome Assessment, Health Care; Schizophrenia | 2020 |
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Olanzapine; Schizophrenia; Treatment Outcome | 2021 |
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain; Young Adult | 2020 |
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Treatment Outcome | 2021 |
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Glucose; Healthy Volunteers; Humans; Insulin; Naltrexone; Narcotic Antagonists; Olanzapine; United States | 2022 |
17 other study(ies) available for naltrexone and olanzapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.
Topics: Animals; Antipsychotic Agents; Appetite Depressants; Appetite Regulation; Behavior, Animal; Benzodiazepines; Delayed-Action Preparations; Drug Interactions; Energy Intake; Feeding Behavior; Female; Injections, Intramuscular; Injections, Intraperitoneal; Leptin; Naltrexone; Narcotic Antagonists; Olanzapine; Random Allocation; Rats; Rats, Wistar; Weight Gain | 2012 |
Effects of lisdexamfetamine in a rat model of binge-eating.
Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Models, Animal; Eating; Feeding Behavior; Female; Idazoxan; Lisdexamfetamine Dimesylate; Naltrexone; Olanzapine; Prazosin; Prodrugs; Raclopride; Rats; Rats, Wistar; Rolipram | 2015 |
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Drug Combinations; Female; Glucose Metabolism Disorders; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Olanzapine; Rats; Rats, Sprague-Dawley; Sex Factors; Weight Gain | 2019 |
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Drug Combinations; Drug Interactions; Female; Humans; Lithium Carbonate; Male; Naltrexone; Narcotic Antagonists; Olanzapine; Valproic Acid; Weight Gain; Young Adult | 2020 |
Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
Topics: Adolescent; Adult; Antipsychotic Agents; Computer Simulation; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Biological; Naltrexone; Narcotic Antagonists; Olanzapine; Young Adult | 2020 |
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?
Topics: Antipsychotic Agents; Humans; Naltrexone; Olanzapine; Schizophrenia; Weight Gain | 2020 |
Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
Topics: Antipsychotic Agents; Area Under Curve; Humans; Naltrexone; Narcotic Antagonists; Olanzapine | 2021 |
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Body Weight; Cigarette Smoking; Cytochrome P-450 CYP3A; Drug Combinations; Female; Food-Drug Interactions; Humans; Liver Failure; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Racial Groups; Renal Insufficiency; Rifampin; Schizophrenia; Sex Factors; Young Adult | 2021 |
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
Topics: Aged; Antipsychotic Agents; Drug Combinations; Female; Humans; Liver Diseases; Male; Middle Aged; Models, Biological; Naltrexone; Narcotic Antagonists; Olanzapine; Severity of Illness Index; Tablets | 2021 |
Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.
Topics: Antipsychotic Agents; Drug Compounding; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Spectrometry, Fluorescence; Tablets | 2022 |
Olanzapine/samidorphan precipitated opioid withdrawal in a patient taking transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Naltrexone; Olanzapine; Substance Withdrawal Syndrome | 2022 |
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain | 2022 |